{"transactions":[{"id":4637620,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-10-08T01:00:06.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027."}],"balance_after":64000,"derivative":{"exercise_price":3.75,"expiration_date":"2036-10-05","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0001193125-26-417233","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526417233/ownership.xml","form_type":"4"}},{"id":4637619,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-08T01:00:06.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":10700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027."}],"balance_after":10700,"source":{"system":"sec-edgar","filing":"0001193125-26-417233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526417233/ownership.xml","form_type":"4"}},{"id":687734,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T01:00:08.000Z","date":"2026-08-12","kind":"sale","planned":true,"acquired":false,"shares":12700,"price":5.29,"value":67183.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-349962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000119312526349962/ownership.xml","form_type":"4"}},{"id":974070,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-12-11T02:45:16.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These share options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.97,"expiration_date":"2026-08-16","underlying":"Ordinary Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001193125-25-314742","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000119312525314742/ownership.xml","form_type":"4"}},{"id":974069,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-11T02:45:16.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":42000,"price":15,"value":630000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025."}],"balance_after":12700,"source":{"system":"sec-edgar","filing":"0001193125-25-314742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000119312525314742/ownership.xml","form_type":"4"}},{"id":974068,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-11T02:45:16.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":42000,"price":5.97,"value":250740.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025."}],"balance_after":54700,"source":{"system":"sec-edgar","filing":"0001193125-25-314742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000119312525314742/ownership.xml","form_type":"4"}},{"id":998653,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-11-15T02:00:04.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":16115,"price":6.79,"value":109420.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.64 to $7.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":12700,"source":{"system":"sec-edgar","filing":"0001193125-25-283619","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000119312525283619/ownership.xml","form_type":"4"}},{"id":1067553,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-08-14T00:00:07.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":76200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026."}],"balance_after":76200,"derivative":{"exercise_price":8.105,"expiration_date":"2030-08-11","underlying":"Ordinary Shares","underlying_shares":76200},"source":{"system":"sec-edgar","filing":"0000950170-25-108286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000095017025108286/ownership.xml","form_type":"4"}},{"id":1067552,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-14T00:00:07.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":12700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026."}],"balance_after":28815,"source":{"system":"sec-edgar","filing":"0000950170-25-108286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000095017025108286/ownership.xml","form_type":"4"}},{"id":1255156,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:30:23.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":3428832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":3428832,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":3428832},"source":{"system":"sec-edgar","filing":"0001104659-25-015739","document":"tm257186-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925015739/tm257186-1_4seq1.xml","form_type":"4"}},{"id":1255155,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2025-02-20T22:30:23.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":5143248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029."}],"balance_after":5143248,"derivative":{"exercise_price":0.1,"expiration_date":"2035-02-20","underlying":"Ordinary Shares","underlying_shares":5143248},"source":{"system":"sec-edgar","filing":"0001104659-25-015739","document":"tm257186-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925015739/tm257186-1_4seq1.xml","form_type":"4"}},{"id":1299704,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-18T02:15:20.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":30601,"price":0.5808,"value":17773.0608,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.5797 to $0.589, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 350,900 ADSs and RSU-style options and other options covering an aggregate of 34,439,286 ordinary shares of the Issuer."}],"balance_after":44327,"source":{"system":"sec-edgar","filing":"0001104659-25-004605","document":"tm253716-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925004605/tm253716-1_4seq1.xml","form_type":"4"}},{"id":1302359,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:19:45.000Z","date":"2025-01-15","kind":"sale","planned":false,"acquired":false,"shares":29096,"price":0.5748,"value":16724.3808,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 15, 2024 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.57 to $0.595, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer."}],"balance_after":41582,"source":{"system":"sec-edgar","filing":"0001104659-25-003775","document":"tm253441-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925003775/tm253441-5_4seq1.xml","form_type":"4"}},{"id":1302358,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:19:45.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":17934,"price":0.5879,"value":10543.3986,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer."}],"balance_after":25711,"source":{"system":"sec-edgar","filing":"0001104659-25-003775","document":"tm253441-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925003775/tm253441-5_4seq1.xml","form_type":"4"}},{"id":1302357,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-01-15T21:19:45.000Z","date":"2025-01-13","kind":"sale","planned":false,"acquired":false,"shares":12539,"price":0.5879,"value":7371.6781,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.58 to $0.603, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 265,806 ADSs and RSU-style options and other options covering an aggregate of 34,888,854 ordinary shares of the Issuer."}],"balance_after":17801,"source":{"system":"sec-edgar","filing":"0001104659-25-003775","document":"tm253441-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465925003775/tm253441-5_4seq1.xml","form_type":"4"}},{"id":1433382,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-08-14T22:00:10.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":32230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025."}],"balance_after":32230,"derivative":{"exercise_price":5.37,"expiration_date":"2029-08-12","underlying":"Ordinary Shares","underlying_shares":32230},"source":{"system":"sec-edgar","filing":"0000950170-24-097290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000095017024097290/ownership.xml","form_type":"4"}},{"id":1433381,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-14T22:00:10.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":16115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025."}],"balance_after":16115,"source":{"system":"sec-edgar","filing":"0000950170-24-097290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000095017024097290/ownership.xml","form_type":"4"}},{"id":1677572,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:52.000Z","date":"2024-01-17","kind":"sale","planned":false,"acquired":false,"shares":30080,"price":0.673,"value":20243.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 17, 2023 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.67 to $0.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer."}],"balance_after":44848,"source":{"system":"sec-edgar","filing":"0001104659-24-004564","document":"tm243270-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004564/tm243270-16_4seq1.xml","form_type":"4"}},{"id":1677571,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-17T22:31:52.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":9304,"price":0.79,"value":7350.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 206,854 ADSs and RSU-style options and other options covering an aggregate of 35,756,832 ordinary shares of the Issuer."}],"balance_after":14104,"source":{"system":"sec-edgar","filing":"0001104659-24-004564","document":"tm243270-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004564/tm243270-16_4seq1.xml","form_type":"4"}},{"id":1677570,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:00:22.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":1696272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 424,068 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 424,068 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1696272,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":1696272},"source":{"system":"sec-edgar","filing":"0001104659-24-004520","document":"tm243270-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004520/tm243270-5_4seq1.xml","form_type":"4"}},{"id":1677569,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T22:00:22.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":7633296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,908,324 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 159,024 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 159,132 Ordinary Shares on January 15, 2028."}],"balance_after":7633296,"derivative":{"exercise_price":0.14,"expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":7633296},"source":{"system":"sec-edgar","filing":"0001104659-24-004520","document":"tm243270-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924004520/tm243270-5_4seq1.xml","form_type":"4"}},{"id":1679788,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:41.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":17257,"price":0.8541,"value":14739.2037,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.813 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 162,071 ADSs and RSU-style options and other options covering an aggregate of 27,017,280 ordinary shares of the Issuer."}],"balance_after":26388,"source":{"system":"sec-edgar","filing":"0001104659-24-003742","document":"tm243270-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924003742/tm243270-1_4seq1.xml","form_type":"4"}},{"id":1679787,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-01-12T22:00:41.000Z","date":"2024-01-11","kind":"sale","planned":false,"acquired":false,"shares":11945,"price":0.8367,"value":9994.3815,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.80 to $0.88, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 162,071 ADSs and RSU-style options and other options covering an aggregate of 27,017,280 ordinary shares of the Issuer."}],"balance_after":18395,"source":{"system":"sec-edgar","filing":"0001104659-24-003742","document":"tm243270-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465924003742/tm243270-1_4seq1.xml","form_type":"4"}},{"id":1790611,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-09-01T23:00:26.000Z","date":"2023-09-01","kind":"sale","planned":false,"acquired":false,"shares":2403,"price":0.78,"value":1874.34,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 158,622 ADSs and RSU-style options and other options covering an aggregate of 27,461,190 ordinary shares of the Issuer."}],"balance_after":3449,"source":{"system":"sec-edgar","filing":"0001104659-23-097853","document":"tm2325388-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923097853/tm2325388-1_4seq1.xml","form_type":"4"}},{"id":1811719,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2023-08-10T00:00:17.000Z","date":"2023-08-07","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024."}],"balance_after":45000,"derivative":{"exercise_price":4.58,"expiration_date":"2028-08-07","underlying":"Ordinary Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-23-017912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924323017912/doc4.xml","form_type":"4"}},{"id":1843281,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-06-28T01:15:46.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":2333,"price":0.92,"value":2146.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 155,103 ADSs and RSU-style options and other options covering an aggregate of 27,496,302 ordinary shares of the Issuer."}],"balance_after":3519,"source":{"system":"sec-edgar","filing":"0001104659-23-075407","document":"tm2317417-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923075407/tm2317417-5_4seq1.xml","form_type":"4"}},{"id":2053539,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-18T02:15:37.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":10057,"price":1.858,"value":18685.906,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.82 to $1.87, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 141,752 ADSs and RSU-style options and other options covering an aggregate of 27,531,414 ordinary shares of the Issuer."}],"balance_after":13351,"source":{"system":"sec-edgar","filing":"0001104659-23-004379","document":"tm231655-17_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923004379/tm231655-17_4seq1.xml","form_type":"4"}},{"id":2053538,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:01:05.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":1798272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 449,568 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 449,568 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1798272,"derivative":{"exercise_price":0.0012,"underlying":"Ordinary Shares","underlying_shares":1798272},"source":{"system":"sec-edgar","filing":"0001104659-23-004369","document":"tm231655-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923004369/tm231655-9_4seq1.xml","form_type":"4"}},{"id":2053537,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-01-18T02:01:05.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":4690224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.26 based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,172,556 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 97,818 Ordinary Shares on January 17, 2027."}],"balance_after":4690224,"derivative":{"exercise_price":0.31,"expiration_date":"2033-01-17","underlying":"Ordinary Shares","underlying_shares":4690224},"source":{"system":"sec-edgar","filing":"0001104659-23-004369","document":"tm231655-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923004369/tm231655-9_4seq1.xml","form_type":"4"}},{"id":2055467,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-13T02:00:42.000Z","date":"2023-01-12","kind":"sale","acquired":false,"shares":18763,"price":1.706,"value":32009.678,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.70 to $1.79, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 99,572 ADSs and RSU-style options and other options covering an aggregate of 21,183,366 ordinary shares of the Issuer."}],"balance_after":24882,"source":{"system":"sec-edgar","filing":"0001104659-23-003534","document":"tm231655-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923003534/tm231655-5_4seq1.xml","form_type":"4"}},{"id":2055466,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-13T02:00:42.000Z","date":"2023-01-11","kind":"sale","acquired":false,"shares":13042,"price":1.7468,"value":22781.7656,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.73 to $1.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 99,572 ADSs and RSU-style options and other options covering an aggregate of 21,183,366 ordinary shares of the Issuer."}],"balance_after":17298,"source":{"system":"sec-edgar","filing":"0001104659-23-003534","document":"tm231655-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923003534/tm231655-5_4seq1.xml","form_type":"4"}},{"id":2065878,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2023-01-05T02:00:27.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":5073,"price":1.694,"value":8593.662,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 92,941 ADSs and RSU-style options and other options covering an aggregate of 21,627,276 ordinary shares of the Issuer."}],"balance_after":6631,"source":{"system":"sec-edgar","filing":"0001104659-23-001088","document":"tm231655-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465923001088/tm231655-1_4seq1.xml","form_type":"4"}},{"id":2168764,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-09-02T01:00:56.000Z","date":"2022-09-01","kind":"sale","acquired":false,"shares":2536,"price":1.9689,"value":4993.1304,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 89,625 ADSs and RSU-style options and other options covering an aggregate of 21,697,500 ordinary shares of the Issuer."}],"balance_after":3316,"source":{"system":"sec-edgar","filing":"0001104659-22-097135","document":"tm2224996-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922097135/tm2224996-1_4seq1.xml","form_type":"4"}},{"id":2180779,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2022-08-18T00:01:32.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023."}],"balance_after":21000,"derivative":{"exercise_price":3.5,"expiration_date":"2027-08-15","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000899243-22-029100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924322029100/doc4.xml","form_type":"4"}},{"id":2220892,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-06-28T01:01:06.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":2562,"price":1.63,"value":4176.06,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 86,335 ADSs and RSU-style options and other options covering an aggregate of 21,732,612 ordinary shares of the Issuer."}],"balance_after":3290,"source":{"system":"sec-edgar","filing":"0001104659-22-074926","document":"tm2219493-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922074926/tm2219493-1_4seq1.xml","form_type":"4"}},{"id":2433413,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-19T02:00:58.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":11096,"price":3.1918,"value":35416.2128,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 74,023 ADSs and RSU-style options and other options covering an aggregate of 21,767,724 ordinary shares of the Issuer."}],"balance_after":12312,"source":{"system":"sec-edgar","filing":"0001104659-22-005053","document":"tm221700-15_4seq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922005053/tm221700-15_4seq.xml","form_type":"4"}},{"id":2435696,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-14T02:01:03.000Z","date":"2022-01-12","kind":"sale","acquired":false,"shares":3046,"price":3.5441,"value":10795.3286,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,689 ADSs and RSU-style options and other options covering an aggregate of 21,908,172 ordinary shares of the Issuer."}],"balance_after":3356,"source":{"system":"sec-edgar","filing":"0001104659-22-004149","document":"tm221700-11_4seq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922004149/tm221700-11_4seq.xml","form_type":"4"}},{"id":2435695,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-14T02:01:03.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":14362,"price":3.5567,"value":51081.3254,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,689 ADSs and RSU-style options and other options covering an aggregate of 21,908,172 ordinary shares of the Issuer."}],"balance_after":15978,"source":{"system":"sec-edgar","filing":"0001104659-22-004149","document":"tm221700-11_4seq.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922004149/tm221700-11_4seq.xml","form_type":"4"}},{"id":2435694,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-14T02:00:26.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":1047480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 261,870 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 261,870 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":1047480,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":1047480},"source":{"system":"sec-edgar","filing":"0001104659-22-004147","document":"tm221700-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922004147/tm221700-5_4seq1.xml","form_type":"4"}},{"id":2435693,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-01-14T02:00:26.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":4690224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 1,172,556 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 97,818 Ordinary Shares on January 12, 2026."}],"balance_after":4690224,"derivative":{"exercise_price":0.6,"expiration_date":"2032-01-12","underlying":"Ordinary Shares","underlying_shares":4690224},"source":{"system":"sec-edgar","filing":"0001104659-22-004147","document":"tm221700-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922004147/tm221700-5_4seq1.xml","form_type":"4"}},{"id":2442862,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2022-01-06T02:04:47.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":5532,"price":4.0642,"value":22483.1544,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 48,517 ADSs and RSU-style options and other options covering an aggregate of 16,390,920 ordinary shares of the Issuer."}],"balance_after":6172,"source":{"system":"sec-edgar","filing":"0001104659-22-001668","document":"tm221700-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465922001668/tm221700-1_4seq1.xml","form_type":"4"}},{"id":2583131,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-09-02T01:00:47.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":2782,"price":5.195,"value":14452.49,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.18 to $5.225, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 45,447 ADSs and RSU-style options and other options covering an aggregate of 16,461,144 ordinary shares of the Issuer."}],"balance_after":3070,"source":{"system":"sec-edgar","filing":"0001104659-21-112179","document":"tm2126797-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921112179/tm2126797-1_4seq1.xml","form_type":"4"}},{"id":2597366,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2021-08-18T22:10:32.000Z","date":"2021-08-16","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 12.5% of the shares in equal quarterly installments over the two-year period following the grant date on August 16, 2021."}],"balance_after":42000,"derivative":{"exercise_price":5.97,"expiration_date":"2026-08-16","underlying":"Ordinary Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000899243-21-033525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924321033525/doc4.xml","form_type":"4"}},{"id":2653099,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-06-29T01:01:06.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":2794,"price":4.37,"value":12209.78,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the sale price per ADS."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 42,389 ADSs and RSU-style options and other options covering an aggregate of 16,461,144 ordinary shares of the Issuer."}],"balance_after":3058,"source":{"system":"sec-edgar","filing":"0001104659-21-086385","document":"tm2118429-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921086385/tm2118429-2_4seq1.xml","form_type":"4"}},{"id":2903956,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-01-20T02:00:29.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":9879,"price":5.6695,"value":56008.9905,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which vested on January 16, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.64 to $5.72, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 28,860 ADSs and RSU-style options and other options covering an aggregate of 16,531,368 ordinary shares of the Issuer."}],"balance_after":13529,"source":{"system":"sec-edgar","filing":"0001104659-21-005544","document":"tm213569-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921005544/tm213569-1_4seq1.xml","form_type":"4"}},{"id":2909172,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-01-13T02:00:08.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":2707,"price":6.1522,"value":16654.0054,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $6.15 to $6.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 25,165 ADSs and RSU-style options and other options covering an aggregate of 16,671,816 ordinary shares of the Issuer."}],"balance_after":3695,"source":{"system":"sec-edgar","filing":"0001104659-21-003590","document":"tm212950-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921003590/tm212950-1_4seq1.xml","form_type":"4"}},{"id":2910505,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-12T02:02:03.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":728160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 182,040 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 182,040 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":728160,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":728160},"source":{"system":"sec-edgar","filing":"0001104659-21-003132","document":"tm212800-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921003132/tm212800-4_4seq1.xml","form_type":"4"}},{"id":2910504,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-01-12T02:02:03.000Z","date":"2021-01-11","kind":"grant","acquired":true,"shares":3260400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.76 based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 815,100 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 67,920 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 68,100 Ordinary Shares on January 11, 2025."}],"balance_after":3260400,"derivative":{"exercise_price":1.03,"expiration_date":"2031-01-11","underlying":"Ordinary Shares","underlying_shares":3260400},"source":{"system":"sec-edgar","filing":"0001104659-21-003132","document":"tm212800-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921003132/tm212800-4_4seq1.xml","form_type":"4"}},{"id":2918969,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2021-01-06T02:00:13.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":4967,"price":5.3279,"value":26463.6793,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2021. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.265 to $5.45, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 18,428 ADSs and RSU-style options and other options covering an aggregate of 12,721,668 ordinary shares of the Issuer."}],"balance_after":6737,"source":{"system":"sec-edgar","filing":"0001104659-21-001175","document":"tm211506-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465921001175/tm211506-1_4seq1.xml","form_type":"4"}},{"id":3040692,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2020-09-03T01:00:28.000Z","date":"2020-09-01","kind":"sale","acquired":false,"shares":2776,"price":8.5149,"value":23637.3624,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which vested on September 1, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price based on prices ranging from $8.505 to $8.635, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 15,352 ADSs and RSU-style options and other options covering an aggregate of 12,791,892 ordinary shares of the Issuer."}],"balance_after":3076,"source":{"system":"sec-edgar","filing":"0001104659-20-101976","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465920101976/a4.xml","form_type":"4"}},{"id":3050736,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2020-08-20T22:32:47.000Z","date":"2020-08-18","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021."}],"balance_after":10500,"derivative":{"exercise_price":9.13,"expiration_date":"2025-08-18","underlying":"Ordinary Shares","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0000899243-20-023085","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924320023085/doc4.xml","form_type":"4"}},{"id":3069078,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2020-08-05T01:01:13.000Z","date":"2020-08-03","kind":"sale","acquired":false,"shares":2788,"price":9.25,"value":25789.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which vested on June 27, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These ADSs were sold in multiple transactions at a price of $9.25. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 12,288 ADSs and RSU-style options and other options covering an aggregate of 12,827,004 ordinary shares of the Issuer."}],"balance_after":3064,"source":{"system":"sec-edgar","filing":"0001104659-20-090468","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465920090468/a4.xml","form_type":"4"}},{"id":3307371,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-01-18T02:30:13.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":561792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.302659 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 140,448 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":561792,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":561792},"source":{"system":"sec-edgar","filing":"0001104659-20-005256","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465920005256/a4.xml","form_type":"4"}},{"id":3307370,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2020-01-18T02:30:13.000Z","date":"2020-01-16","kind":"grant","acquired":true,"shares":2515536,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.57 based on an exchange rate of $U.S. 1.302659 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 628,884 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 52,512 Ordinary Shares on January 16, 2024."}],"balance_after":2515536,"derivative":{"exercise_price":0.74,"expiration_date":"2030-01-16","underlying":"Ordinary Shares","underlying_shares":2515536},"source":{"system":"sec-edgar","filing":"0001104659-20-005256","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465920005256/a4.xml","form_type":"4"}},{"id":3310572,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2020-01-16T01:01:44.000Z","date":"2020-01-14","kind":"sale","acquired":false,"shares":3236,"price":5.1347,"value":16615.8892,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 9,122 ADSs and RSU-style options and other options covering an aggregate of 9,784,788 ordinary shares of the Issuer."}],"balance_after":3166,"source":{"system":"sec-edgar","filing":"0001104659-20-004420","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465920004420/a4.xml","form_type":"4"}},{"id":3315980,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2020-01-08T01:00:44.000Z","date":"2020-01-06","kind":"sale","acquired":false,"shares":5900,"price":1.2,"value":7080.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,318 ADSs and RSU-style options and other options covering an aggregate of 9,823,200 ordinary shares of the Issuer."}],"balance_after":5804,"source":{"system":"sec-edgar","filing":"0001104659-20-002080","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465920002080/a4.xml","form_type":"4"}},{"id":3424672,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-09-04T01:00:29.000Z","date":"2019-09-01","kind":"grant","acquired":true,"shares":140448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.21721 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 35,112 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the first of each September from September 1, 2021 through September 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":140448,"derivative":{"exercise_price":0.0012,"underlying":"Ordinary Shares","underlying_shares":140448},"source":{"system":"sec-edgar","filing":"0001104659-19-048518","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919048518/a4.xml","form_type":"4"}},{"id":3424671,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and CFO"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-09-04T01:00:29.000Z","date":"2019-09-01","kind":"grant","acquired":true,"shares":628872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.22 based on an exchange rate of $U.S. 1.21721 to GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 157,218 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the first of each month from October 1, 2020 through August 1, 2023 and 13,119 Ordinary Shares on September 1, 2023."}],"balance_after":628872,"derivative":{"exercise_price":0.27,"expiration_date":"2029-09-01","underlying":"Ordinary Shares","underlying_shares":628872},"source":{"system":"sec-edgar","filing":"0001104659-19-048518","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919048518/a4.xml","form_type":"4"}},{"id":3435839,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2019-08-16T20:20:53.000Z","date":"2019-08-15","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020"}],"balance_after":10500,"derivative":{"exercise_price":20.34,"expiration_date":"2024-08-15","underlying":"Ordinary Shares","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0000899243-19-021965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924319021965/doc4.xml","form_type":"4"}},{"id":3476714,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-06-28T00:00:59.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":140448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26828 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 35,112 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the twenty-seventh of each June from June 27, 2021 through June 27, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":140448,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":140448},"source":{"system":"sec-edgar","filing":"0001104659-19-038003","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919038003/a4.xml","form_type":"4"}},{"id":3476713,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-06-28T00:00:59.000Z","date":"2019-06-27","kind":"grant","acquired":true,"shares":628872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.53 based on an exchange rate of $U.S. 1.26828 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 157,218 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the twenty-seventh of each month from July 27, 2020 through May 27, 2022 and 13,119 Ordinary Shares on June 27, 2023."}],"balance_after":628872,"derivative":{"exercise_price":0.68,"expiration_date":"2029-06-27","underlying":"Ordinary Shares","underlying_shares":628872},"source":{"system":"sec-edgar","filing":"0001104659-19-038003","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919038003/a4.xml","form_type":"4"}},{"id":3694363,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2019-01-17T02:30:57.000Z","date":"2019-01-14","kind":"sale","acquired":false,"shares":3084,"price":5.3694,"value":16559.2296,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 8,354,784 ordinary shares of the Issuer."}],"balance_after":3318,"source":{"system":"sec-edgar","filing":"0001104659-19-002163","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919002163/a4.xml","form_type":"4"}},{"id":3699852,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-09T02:01:37.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":280896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 70,224 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":280896,"derivative":{"exercise_price":0.0013,"underlying":"Ordinary Shares","underlying_shares":280896},"source":{"system":"sec-edgar","filing":"0001104659-19-001302","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919001302/a4.xml","form_type":"4"}},{"id":3699851,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2019-01-09T02:01:37.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":1257744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 314,436 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 26,238 Ordinary Shares on January 4, 2023."}],"balance_after":1257744,"derivative":{"exercise_price":0.89,"expiration_date":"2029-01-04","underlying":"Ordinary Shares","underlying_shares":1257744},"source":{"system":"sec-edgar","filing":"0001104659-19-001302","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465919001302/a4.xml","form_type":"4"}},{"id":3843044,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2018-08-16T00:03:53.000Z","date":"2018-08-13","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019."}],"balance_after":9000,"derivative":{"exercise_price":46.7,"expiration_date":"2023-08-13","underlying":"Ordinary Shares","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-18-022506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924318022506/doc4.xml","form_type":"4"}},{"id":3984765,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2018-03-23T01:01:08.000Z","date":"2018-03-20","kind":"sale","acquired":false,"shares":600000,"price":1.71,"value":1026000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares whose sale is reported on this line are represented by American Depositary Shares (\"ADSs\"). Each ADS represents six Ordinary Shares. The Ordinary Shares were obtained from the partial exercise of an option that was granted on March 16, 2015."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Ordinary Shares whose sale is reported on this line are represented by American Depositary Shares (\"ADSs\"). Each ADS represents six Ordinary Shares. The Ordinary Shares were obtained from the partial exercise of an option that was granted on March 16, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of $1.71 per Ordinary Share was derived from the sale price of $10.27 per ADS on March 20, 2018 divided by six."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-019665","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465918019665/a4.xml","form_type":"4"}},{"id":4097504,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T22:21:06.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":153648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 38,412 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 38,412 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":153648,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":153648},"source":{"system":"sec-edgar","filing":"0001104659-18-002677","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465918002677/a4.xml","form_type":"4"}},{"id":4097503,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T22:21:06.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":687984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00.  The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 171,996 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 14,333 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022."}],"balance_after":687984,"derivative":{"exercise_price":1.3,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":687984},"source":{"system":"sec-edgar","filing":"0001104659-18-002677","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465918002677/a4.xml","form_type":"4"}},{"id":4230277,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2017-08-17T20:21:14.000Z","date":"2017-08-10","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 10, 2018."}],"balance_after":9000,"derivative":{"exercise_price":18.1,"expiration_date":"2022-08-10","underlying":"Ordinary Shares","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000899243-17-020604","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924317020604/doc4.xml","form_type":"4"}},{"id":4473102,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2017-02-01T23:39:53.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy.The option vests as to 25% of the shares on February 1, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 1, 2021."}],"balance_after":18000,"derivative":{"exercise_price":28.8,"expiration_date":"2022-02-01","underlying":"Ordinary Shares","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000899243-17-002388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000089924317002388/doc4.xml","form_type":"4"}},{"id":4487871,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":23632,"kind":"person","name":"Rawcliffe Adrian","position":1,"cik":"0001555851","reported_name":"Rawcliffe Adrian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2017-01-18T22:02:00.000Z","date":"2017-01-13","kind":"grant","acquired":true,"shares":2072976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021."}],"balance_after":2072976,"derivative":{"exercise_price":0.72,"expiration_date":"2027-01-13","underlying":"Ordinary Shares","underlying_shares":2072976},"source":{"system":"sec-edgar","filing":"0001104659-17-002824","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555851/000110465917002824/a4.xml","form_type":"4"}}]}